Low Antigen Density Tumor Cells: An Obstacle to Effective Autologous Bone Marrow Purging?

References

• Metzgar RS, Borowitz MJ, Jones NH, Dowell BL. Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues. J Exp Med 1981; 154: 1249–1254
   PubMed Web of Science ®Google Scholar
• Jones NG, Borowitz MJ, Metzgar R. Characterization and distribution of a 24,000-molecular weight antigen defined by a monoclonal antibody (DU-ALL-1) elicited to common acute lymphoblastic leukemia (cALL) cells. Leukemia Res 1982; 6: 449–464
   PubMed Web of Science ®Google Scholar
• Kemshead JT, Goldman A, Fritschy J. Use of panels of monoclonal antibodies in the differential diagnosis of neuroblastoma and lymphoblastic disorders. Lancet 1983; i: 12–15
   Google Scholar
• McMichael AJ, Fabre JW. Monoclonal Antibodies in Clinical Medicine. Academic Press, New York 1982
   Google Scholar
• Goldman A, Vivian G, Gordon I. Immunolocalization of neuroblastoma using radiolabeled monoclonal antibody UJ13A. J Pediatr 1984; 105: 252–256
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Deland F, Kim E. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978; 298: 1384–1388
   PubMed Web of Science ®Google Scholar
• Scheinberg DA, Strand M, Gansow OA. Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Science 1982; 215: 1511–1513
   PubMed Web of Science ®Google Scholar
• Yolken RH, Bishop CA, Townsend TR. Infectious gastroenteritis in bone-marrow-transplant recipients. N Engl J Med 1982; 306: 1009–1012
   Web of Science ®Google Scholar
• Jansen J, Falkenburg JHF, Stepan DE, LeBien TW. Removal of neoplastic cells from autologous bone marrow grafts with monoclonal antibodies. Sem Hematol 1984; 21: 164–181
   PubMed Web of Science ®Google Scholar
• Graham-Pole J, Gee AP. Cancer treatment using autologous bone marrow infusions. J Fla Med Assn 1984; 71: 336–343
   PubMedGoogle Scholar
• Atkinson K. Clinical bone marrow transplantation: Current status. Transplant Proc 1984; 16: 1009–1015
   PubMed Web of Science ®Google Scholar
• Thomas ED, Storb R, Clift RA. Bone marrow transplantation. N Engl J Med 1975; 292: 32–43; 895–902
   Google Scholar
• Storb R, Thomas ED, Buckner CD. Marrow transplantation in thirty “untransfused” patients with severe aplastic anemia. Ann Intern Med 1980; 92: 30–36
   PubMed Web of Science ®Google Scholar
• Storb R, Prentice RL, Buckner CD. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. N Engl J Med 1983; 308: 302–307
   PubMed Web of Science ®Google Scholar
• Chu E, Umetsu D, Rosen F, Geha RS. Major histocompatibility restriction of antigen recognition by T-cells in a recipient of haplotype mismatched human bone marrow transplantation. J Clin Invest 1983; 73: 1124–1128
   Google Scholar
• Flipovich AH, Ramsay NKC, Warkentin PI. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation. Lancet 1982; 1: 1266–1269
   PubMed Web of Science ®Google Scholar
• Kaiser H, Stuart RK, Colvin M. Autologous bone marrow transplantation in acute leukemia: A pilot study utilizing in vitro incubation of autologous marrow with 4-hydroperoxycyclophosphamide (4HC) prior to cryopreservation (Abstr.). Exp Hematol 1981; 9: 190
   Google Scholar
• Phillips GL, Fay JW, Herzig GP. Intensive l,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. Cancer 1983; 52: 1792–1802
   PubMed Web of Science ®Google Scholar
• Phillips GL, Herzig RH, Lazarus HM. Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow. N Engl J Med 1984; 310: 1557–1561
   PubMed Web of Science ®Google Scholar
• Dicke KA, Zander A, Spitzer G. Autologous bone marrow transplantation in relapsed adult acute leukemia. Lancet 1979; 1: 514–517
   PubMed Web of Science ®Google Scholar
• Wells JR, Billing R, Herzog P. Autotransplantation after in vitro immunotherapy of lymphoblastic leukemia. Exp Hematol 1979; 7: 164–169
   PubMed Web of Science ®Google Scholar
• August CS, Serota FT, Koch PA. Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous marrow reconstitution. J Clin Oncol 1984; 2: 609–616
   PubMed Web of Science ®Google Scholar
• Treleaven JG, Gibson FM, Ugelstad J. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet 1984; 1: 70–73
   PubMed Web of Science ®Google Scholar
• Netzel B, Haas RJ, Rodt H. Immunological conditioning of bone marrow for autotransplantation in childhood acute lymphoblastic leukemia. Lancet 1980; 1: 1330–1332
   PubMed Web of Science ®Google Scholar
• Vitetta ES, Krolick KA, Uhr JW. Neoplastic B cells for antibody-ricin A chain immunotoxins. Immunol Rev 1982; 62: 159–183
   PubMed Web of Science ®Google Scholar
• Humphrey JH. Haemolytic efficiency of rabbit IgG anti-Forssman antibody and its augmentation by anti-rabbit IgG. Nature 1967; 216: 1295–1296
   PubMed Web of Science ®Google Scholar
• Borsos T, Circolo A. Binding and activation of C1 by bound IgG: Activation depends on cell surface hapten density. Molec Immunol 1983; 20: 433–438
   PubMed Web of Science ®Google Scholar
• Circolo A, Borsos T. Lysis of hapten-labeled cells by anti-hapten IgG and complement: Effect of cell surface hapten density. J Immunol 1982; 128: 1118–1121
   PubMed Web of Science ®Google Scholar
• Lo TN, Boyle MDP. Relationship between intracellular cyclic adenosine 3 ′:5 ′-monophosphate level of tumor cells and their sensitivity to killing by antibody and complement. Cancer Res 1979; 39: 3156–3162
   PubMed Web of Science ®Google Scholar
• Ohanian SH, Schlager SI. Humoral immune killing of nucleated cells. I. Mechanisms of complement-mediated attack and target cell defense. CRC Crit Rev Immunol 1981; 1: 165–209
   Google Scholar
• Schlager SI, Boyle MDP, Ohanian SH, Borsos T. Effect of inhibiting DNA, RNA, and protein synthesis of tumor cells on their susceptibility to killing by antibody and complement. Cancer Res 1977; 37: 1432–1437
   PubMed Web of Science ®Google Scholar
• Ohanian SH, Yamazaki M, Schlager SI, Faibisch M. Cell growth-dependent variation in the sensitivity of human and mouse tumor cells to complement-mediating killing. Cancer Res 1983; 43: 491–495
   PubMed Web of Science ®Google Scholar
• Bahler DW, Lord EM, Kennel SJ, Horan PK. Heterogeneity and clonal variation related to cell surface expression of a mouse lung tumor-association antigen quantified using flow cytometry. Cancer Res 1984; 144: 3317–3323
   Google Scholar
• Boyle MDP. Is the membrane attack complex of complement an enzyme. Molec Cell Biochem 1984; 61: 5–15
   PubMed Web of Science ®Google Scholar
• Burchiel SW, Martin JC, Imai K. Heterogeneity of HLA-A, B, la-like, and melanoma-associated antigen expression by human melanoma cell lines analyzed with monoclonal antibodies and flow cytometry. Cancer Res 1982; 42: 4110–4115
   PubMed Web of Science ®Google Scholar
• Wilson BS, Kaya NE, Imai K, Ferrone S. Heterogeneity of human melanoma-associated antigens defined by monoclonal antibodies and conventional xenoantisera. Cancer Immunol Immunother 1982; 13: 69–74
   PubMed Web of Science ®Google Scholar
• Daar AS, Fabre JW. The membrane antigens of human colerectal cancer cells: Demonstration with monoclonal antibodies of heterogeneity within and between tumours and of anomalous expression of HLA-DR. Eur J Cancer Clin Oncol 1983; 19: 209–220
   PubMedGoogle Scholar
• Wikstrand CJ, Bigner SH, Bigner DD. Demonstration of complex antigenic heterogeneity in a human glioma cell line and derived clones by specific monoclonal antibodies. Cancer Res. 1983; 43: 3327–3334
   PubMed Web of Science ®Google Scholar
• Gold DV, Shochat D, Primus FJ. Differential expression of tumor-associated antigens in human colon carcinomas xenografted into nude mice. I Natl Cancer Inst 1983; 71: 117–124
   PubMed Web of Science ®Google Scholar
• Taupier MA, Kearney JF, Leibson PJ. Nonrandom escape of tumor cells from immune lysis due to intraclonal fluctuations in antigen expression. Cancer Res 1983; 43: 4050–4056
   PubMed Web of Science ®Google Scholar
• Look AT, Melvin SL, Brown LK. Quantitative variation of the common acute lymphoblastic leukemia antigen (gp100) on leukemic marrow blasts. J Clin Invest 1984; 73: 1617–1628
   PubMed Web of Science ®Google Scholar
• Schroff RW, Farrell MM, Klein RA. T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic leukemia patients. J Immunol 1984; 133: 1641–1648
   PubMed Web of Science ®Google Scholar
• Young WW, Jr., Tamura Y, Johnson HS, Miller DA. Decreased glycolipid antigen expression in lymphoma cell variants escaping from anti-glycolipid serotherapy. J Exp Med 1983; 157: 24–33
   PubMed Web of Science ®Google Scholar
• Leibson PJ, Schreiber H, Liken MR. Time-dependent resistance of susceptibility of tumor cells to cytotoxic antibody after exposure to a chemotherapeutic agent. Proc Natl Acad Sci (USA) 1978; 75: 6202–6206
   PubMed Web of Science ®Google Scholar
• Leibson PJ, Loken MR, Shapiro SJ, Schreiber H. Direct determination of the influence of the cell cycle on the survival of tumor cells exposed to cytotoxic antibodies. Cancer Res 1980; 40: 56–60
   PubMed Web of Science ®Google Scholar
• Shapiro SJ, Leibson PJ, Loken MR, Schreiber H. Changes in susceptibility to cytotoxic antibody among tumor cells surviving exposure to chemotherapeutic agents. Cancer Res 1982; 42: 2622–2627
   PubMed Web of Science ®Google Scholar
• Greiner JW, Hand PH, Noguchi P. Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment. Cancer Res 1984; 44: 3208–3214
   PubMed Web of Science ®Google Scholar
• Giacomini P, Aguzzi A, Pestka S. Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA-and tumor-associated antigens by human melanoma cells. J Immunol 1984; 133: 1649–1655
   PubMed Web of Science ®Google Scholar
• Liao SK, Kwong PC, Khosravi M, Dent PB. Enhanced expression of melanoma-associated antigens and beta2-microglobulin on cultured human melanoma cells by interferon. J Natl Cane Inst 1982; 68: 19–25
   PubMed Web of Science ®Google Scholar
• Imai K, Ng A-K, Glassy M, Ferrone S. Differential effect of interferon on the expression of tumor-associated antigens and histocompatibility antigens on human melanoma cells: Relationship to immune lysis mediated by monoclonal antibodies. J Immunol 1981; 127: 505–508
   PubMed Web of Science ®Google Scholar
• Basham TY, Bourgeade MG, Creasey AA, Merigan TC. Interferon increases HLA synthesis in melanoma cells: Interferon-resistant and-sensitive cell lines. Proc Natl Acad Sci (USA) 1982; 79: 3265–3269
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Plicinik BA, Rogentine GN. Unmasking of human lymphoid cell heteroantigens by neuraminidase treatment. J Natl Cancer Inst 1972; 48: 1271–1276
   PubMed Web of Science ®Google Scholar
• Gibofski A, Terasaki PI. Trypsinization of lymphocytes for HLA typing. Transplantation 1972; 13: 192–194
   PubMedGoogle Scholar
• Braun WE, Grecek DR, Murphy JJ. Expanded HL-A phenotypes of human peripheral lymphocytes after trypsinization. Transplantation 1972; 13: 337–339
   PubMed Web of Science ®Google Scholar
• Boyle MDP, Borsos T. Tissue damage caused by the direct and indirect action of complement. Reticuloendothelial Society Tretise on Immunopathology, H. Friedman, S. Reichard, M. Escobar. Plenum Press, New York, 43–76
   Google Scholar
• Langone JJ, Boyle MDP, Borsos T. Studies on the interaction between protein A and immunoglobulin G.I. Effect of protein A on the functional activity of IgG. J Immunol 1978; 121: 327–332
   PubMed Web of Science ®Google Scholar
• Langone JJ, Boyle MDP, Borsos T. Studies on the interaction between protein A and immunoglobulin G. II. Composition and activity of complexes formed between protein I and IgG. J Immunol 1978; 121: 333–338
   PubMed Web of Science ®Google Scholar
• Mota G, Ghetie V, Sjoquist J. Characterization of the soluble complex formed by reacting rabbit IgG with protein A of 5. aureus. Immunochemistry 1978; 15: 639–642
   PubMedGoogle Scholar
• Staienheim G, Gotze O. Consumption of human complement components by complexes of IgG with protein A of Staphylococcus aureus. Immunochemistry 1973; 10: 501–507
   PubMedGoogle Scholar
• Vogel CW, Muller-Eberhard H. Induction of immune cytolysis: Tumor cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase. Proc Natl Acad Sci (USA) 1981; 78: 7707–7711
   PubMed Web of Science ®Google Scholar
• Minta JO, Gee AP. Purification and quantitation of the components of the alternative complement pathway. Methods in Enzymology-Immunochemical Techniques. Academic Press, New York, Vol. 93: 375–408, Part F
   Google Scholar